We are proud to report a successful presence of COVend at Euroanaesthesia 2025, held in Lisbon from 25–27 May. Organised by our project partners at European Society of Anaesthesiology and Intensive Care (ESAIC), the event is one of Europe’s leading congresses for anaesthesia and intensive care professionals. This year’s edition brought together thousands of experts from across Europe and beyond to explore the latest in critical care innovation, COVend included.

Spotlight on ARDS and COVend clinical trial

A standout session by Dr. Benjamin Friedrichson from DSG Frankfurt / Goethe University Frankfurt, who presented “ARDS in Europe: Data and Clinical Trials” at the ESAIC Hub. The session drew an impressive audience of over 150 participants, reflecting significant interest in the topic and the work of the COVend consortium. Dr. Friedrichson’s presentation not only highlighted the clinical relevance of Acute Respiratory Distress Syndrome (ARDS) in the post-COVID-19 context but also showcased COVend as a leading initiative in the development of innovative therapeutic strategies against ARDS and COVID-19. This strong turnout and engagement mark a noteworthy milestone for the project and affirm the growing visibility of its work within the medical and scientific community.

Project Display at the Venue

In addition to the session, a dedicated COVend project display was featured onsite, allowing attendees to learn more about our objectives, clinical research design and current achievements. We are proud to see COVend highlighted in such a prominent forum and grateful to our partners and audience for contributing to the discussion on future treatments for ARDS.

Want to know more about the congress? Visit euroanaesthesia.org

A huge thank you to Benjamin and the ESAIC team for your excellent work and support!